NCT05575024 Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane
| NCT ID | NCT05575024 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Acute Kidney Injury Due to Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 98 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 98 participants in total. It began in 2024-01-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 years * Sepsis related acute kidney injury requiring continuous renal replacement therapy Exclusion Criteria: • No monitoring of blood pressure and ECG
Contact & Investigator
Seung Seok Han, M.D.
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT05575024 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury Due to Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05575024 currently recruiting?
Yes, NCT05575024 is actively recruiting participants. Contact the research team at hansway7@snu.ac.kr for enrollment information.
Where is the NCT05575024 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05575024 clinical trial?
NCT05575024 is sponsored by Seoul National University Hospital. The principal investigator is Seung Seok Han, M.D. at Seoul National University Hospital. The trial plans to enroll 98 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.